CN1817346A - Benzoyl metronidazole dispersion tablets and preparation thereof - Google Patents
Benzoyl metronidazole dispersion tablets and preparation thereof Download PDFInfo
- Publication number
- CN1817346A CN1817346A CN 200610066058 CN200610066058A CN1817346A CN 1817346 A CN1817346 A CN 1817346A CN 200610066058 CN200610066058 CN 200610066058 CN 200610066058 A CN200610066058 A CN 200610066058A CN 1817346 A CN1817346 A CN 1817346A
- Authority
- CN
- China
- Prior art keywords
- parts
- lubricant
- filler
- consumption
- benzoic methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CUUCCLJJOWSASK-UHFFFAOYSA-N metronidazole benzoate Chemical compound CC1=NC=C([N+]([O-])=O)N1CCOC(=O)C1=CC=CC=C1 CUUCCLJJOWSASK-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 239000006185 dispersion Substances 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title claims description 5
- 239000000945 filler Substances 0.000 claims abstract description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
- XWLAHIBWPWGAQY-UHFFFAOYSA-N CC1=C(NC=C1)[N+](=O)[O-] Chemical compound CC1=C(NC=C1)[N+](=O)[O-] XWLAHIBWPWGAQY-UHFFFAOYSA-N 0.000 claims description 20
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 20
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 11
- 239000007919 dispersible tablet Substances 0.000 claims description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 11
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 10
- 239000011230 binding agent Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 7
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 7
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- -1 benzoic methyl nitroazoles Chemical class 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 235000019890 Amylum Nutrition 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 206010013786 Dry skin Diseases 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 5
- 229960000282 metronidazole Drugs 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000007938 effervescent tablet Substances 0.000 description 3
- 239000002423 protozoacide Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000004957 nitroimidazoles Chemical class 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
A dispersing tablet of benzoyl metronidazole is proportionally prepared from benzoyl metronidazole and medicinal additives including disintegrant and filler. Its advantages are high curative effect and quickly taking its effect. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to the improvement pharmaceutical dosage form of benzoic methyl nitroazole, it compares rapid-action with common benzoic methyl nitroazole capsule, and the rapid release effect is obvious, and curative effect is conclusive.
Background technology
Benzoic methyl nitroazole (Benzoylmetronidazole) has another name called metronidazole benzoyl ester, is the nitroimidazoles medicine that anaerobe resistant of new generation, protozoacide infect.Oral back in gastrointestinal tract in several hours hydrolysis discharge metronidazole, pretend and use identically with metronidazole, be used for the treatment of anaerobe and parasitic infection.Now in tens country's listings such as English, method, moral, day, in November, 1993, this medicine was the infection essential drugs by The World Health Organization's approval to benzoic methyl nitroazole.Hebei Pharmaceutical Factory, Tianjin City at first succeeds in developing this product at home in nineteen ninety-five, and has developed the oral administration mixed suspension dosage form.At present, Shang Shi dosage form mainly contains capsule and oral administration mixed suspension at home, and is widely used clinically.
The oral back of benzoic methyl nitroazole is hydrolyzed into the metronidazole that plays a major role at intestinal, and the bactericidal mechanism of metronidazole is not illustrated as yet fully, and the nitroreductase of anaerobe plays an important role in the energy metabolism of sensitive strain.The nitroreduction of this product becomes a kind of cell toxicant, thereby acts on the DNA metabolic process of antibacterial, makes the fracture of its helical structure or blocks it and transcribe and duplicate and cause cell death.The mechanism of anti-ameba ruptures the protozoacide nitrogen chain for suppressing its redox reaction.As anaerobe resistant of new generation, protozoacide infection medicine, benzoic methyl nitroazole has oral absorption rapidly, fully, long half time, characteristics such as side effect is little.
Benzoic methyl nitroazole in the market mostly is common capsule and dry suspension, capsule and dried suspendible are the widely used oral dosage forms of field of medicaments, it has takes and stores and transports convenient and the stable advantage of medicine, but benzoic methyl nitroazole is often fully absorbed because of the medicine stripping slowly influences medicine.In addition, because each taking dose is bigger, often make troubles for the patient of old man, child and dysphagia.Require at present every day three times in the clinical treatment, each 2.The result of clinical practice shows that the rapid release problem of benzoic methyl nitroazole is unresolved all the time.
What have the rapid release function comprises dosage forms such as dispersible tablet, effervescent tablet.The characteristics of dispersible tablet (being advantage) are that tablet is met behind the water in the short as far as possible time (generally in 3 minutes) disintegrate and become very granule and form uniform suspension, therefore, compare with general tablet, dispersible tablet has good dispersing state, and disintegration time is short, the medicine stripping is rapid, absorb soon bioavailability height, characteristics such as taking convenience, can swallow, chew to contain and suck, especially be fit to old, young and the patient of difficulty that swallows.With effervescent tablet relatively, dispersible tablet does not need effervescent (as carbonate and solid organic acid) and water soluble adjuvant, does not need the gentle relative temperature in control room, and instructions of taking various (effervescent tablet can only water in dissolving back oral).In addition, the dispersible tablet production technology is identical with common non-coated tablet, and no specific (special) requirements does not need vacuum lyophilization and extra package, and production cost is low.Therefore advantage is conspicuous.
Summary of the invention
The present invention gropes through a large amount of tests, is developed into benzoyl metronidazole dispersion tablets, has solved the shortcoming that the conventional dosage forms onset is slow, bioavailability is low, has improved curative effect, has reduced side effect.
On the one hand, the invention provides a kind of pharmaceutical composition of benzoyl metronidazole dispersion tablets, contain benzoic methyl nitroazole and suitable pharmaceutic adjuvant in the said composition, the pharmaceutic adjuvant in the present composition includes but not limited to (benzoic methyl nitroazole is by 100 parts of calculating):
A. disintegrating agent:
Microcrystalline Cellulose: consumption is 2～30 parts;
Polyvinylpolypyrrolidone: consumption is 3～40 parts;
Carboxymethyl starch sodium: consumption is 3～15 parts;
Low-substituted hydroxypropyl cellulose: consumption is 2～16 parts;
Or cross-linking sodium carboxymethyl cellulose: consumption is 2～16 parts.
Preferred polyvinylpolypyrrolidone, 3～40 parts.
B. filler:
Amylum pregelatinisatum: consumption is 2～50 parts;
Dextrin: consumption is 2～30 parts;
Lactose: consumption is 2～30 parts;
Microcrystalline Cellulose: consumption is 2～30 parts;
Mannitol: consumption is 2～10 parts;
Preferably: shared 4～30 parts of lactose and microcrystalline Cellulose.
C. binding agent
Polyvinylpyrrolidone aqueous solution, concentration range are 1～15%, and consumption is 2～20 parts;
Starch slurry, consumption are 2～20 parts;
Or the hydroxypropyl emthylcellulose aqueous solution, consumption is 2～20 parts.
Preferred adhesive is 10% polyvinylpyrrolidone aqueous solution, 10 parts of consumptions.
D. lubricant:
Stearic acid: consumption is 0.2～2.5 part;
Polyethylene Glycol: consumption is 0.2～2.5 part (Polyethylene Glycol of multi-purpose solid);
Magnesium stearate: consumption is 0.2～2.5 part;
Or Pulvis Talci: consumption is 2～20 parts.
Preferred magnesium stearate, 0.2～2.5 part.
In the above-mentioned composition, most preferably comprise 100 parts of benzoic methyl nitroazoles, 15 parts of disintegrating agents, 10 parts of 30 parts of binding agents of filler, 0.2 part of lubricant.
The specific embodiment
Further set forth the present invention below in conjunction with specific embodiments, but not as limitation of the present invention.
Embodiment 1:1000 sheet consumption
Benzoic methyl nitroazole 320.0g
Lactose 55.0g
Microcrystalline Cellulose 45.0g
Crospolyvinylpyrrolidone 40.0g
10% polyvinylpyrrolidone K29/32 aqueous solution 10.0g
Magnesium stearate 4.6g
Preparation technology:
120 mesh sieves will be crossed after the benzoic methyl nitroazole micronized, again with polyvinylpolypyrrolidone, lactose, the microcrystalline Cellulose mix homogeneously of recipe quantity, with 10% polyvinylpyrrolidone aqueous solution is binding agent system soft material, 16 mesh sieves are granulated, 50 ℃ of-60 ℃ of dryings, 14 mesh sieve granulate add the magnesium stearate mixing, make tablet.
Embodiment 2:1000 sheet consumption
Benzoic methyl nitroazole 320.0g
Amylum pregelatinisatum 30.0g
Microcrystalline Cellulose 60.0g
Carboxymethyl starch sodium 45.0g
10% polyvinylpyrrolidone K29/32 aqueous solution 10.0g
Magnesium stearate 4.6g
Preparation technology:
120 mesh sieves will be crossed after the benzoic methyl nitroazole micronized, again with carboxymethyl starch sodium, amylum pregelatinisatum, the microcrystalline Cellulose mix homogeneously of recipe quantity, with 10% polyvinylpyrrolidone aqueous solution is binding agent system soft material, 16 mesh sieves are granulated, 50 ℃ of-60 ℃ of dryings, 14 mesh sieve granulate add the magnesium stearate mixing, make tablet.
More than described the preferred embodiment for the present invention, so it is not in order to limit the present invention.Those skilled in the art can not depart from the improvement of category of the present invention and spirit to embodiment disclosed herein.
Claims (7)
1, benzoyl metronidazole dispersion tablets, contain the benzoic methyl nitroazole and the pharmaceutic adjuvant for the treatment of effective dose, it is characterized in that described pharmaceutic adjuvant comprises disintegrating agent and filler, wherein disintegrating agent is selected from least a of microcrystalline Cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose; This filler is selected from least a in amylum pregelatinisatum, dextrin, lactose, microcrystalline Cellulose, the mannitol.
2, the described dispersible tablet of claim 1, wherein by 100 parts of benzoic methyl nitroazoles, described disintegrating agent consumption is 2～50 parts, the consumption of described filler is 5～100 parts.
3, the described dispersible tablet of claim 2, wherein pharmaceutic adjuvant also comprises at least a in binding agent, the lubricant, described binding agent is selected from least a in polyvinylpyrrolidone aqueous solution, starch slurry, the hydroxypropyl emthylcellulose aqueous solution, lubricant is selected from least a in stearic acid, magnesium stearate, Pulvis Talci, Polyethylene Glycol, the Stepanol MG, press 100 parts of calculating of benzoic methyl nitroazole, described adhesive consumption is 2～25 parts, described wetting agent consumption is 5～20 parts, and lubricant is 0.1～20 part.
4, the described dispersible tablet of claim 3, wherein disintegrating agent is a polyvinylpolypyrrolidone, and filler is a lactose, and binding agent is the polyvinylpyrrolidone aqueous solution; Lubricant is a magnesium stearate.
5, the described dispersible tablet of claim 4 is pressed 100 parts of calculating of benzoic methyl nitroazole, and wherein disintegrating agent comprises 3～40 parts of polyvinylpolypyrrolidone, and filler comprises totally 10～50 parts of lactose and microcrystalline Cellulose; Binding agent is that concentration range is 2～20 parts of the polyvinylpyrrolidone aqueous solutions of 1～15% (g/g); Lubricant is 0.1～2.5 part of a magnesium stearate.
6, the described dispersible tablet of claim 5 is pressed 100 parts of calculating of benzoic methyl nitroazole, and wherein the disintegrating agent polyvinylpolypyrrolidone is 15 parts, and filler comprises totally 30 parts of lactose and microcrystalline Cellulose; Binding agent is that concentration range is 10 parts of the polyvinylpyrrolidone aqueous solutions of 10% (g/g); Lubricant is 0.2 part of a magnesium stearate.
7, the preparation method of the described dispersible tablet of claim 1～6 is: will cross 120 mesh sieves after the benzoic methyl nitroazole micronized, again with the adjuvant mix homogeneously of recipe quantity, with 10% polyvinylpyrrolidone aqueous solution is binding agent system soft material, 16 mesh sieves are granulated, 50 ℃ of-60 ℃ of dryings, 14 mesh sieve granulate add the magnesium stearate mixing, make tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610066058 CN1817346A (en) | 2006-03-28 | 2006-03-28 | Benzoyl metronidazole dispersion tablets and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610066058 CN1817346A (en) | 2006-03-28 | 2006-03-28 | Benzoyl metronidazole dispersion tablets and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1817346A true CN1817346A (en) | 2006-08-16 |
Family
ID=36917675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610066058 Pending CN1817346A (en) | 2006-03-28 | 2006-03-28 | Benzoyl metronidazole dispersion tablets and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1817346A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102349894A (en) * | 2011-08-18 | 2012-02-15 | 海南良方医药有限公司 | Benzoylmetronidazole composition and preparation method thereof |
| CN104586749A (en) * | 2014-12-25 | 2015-05-06 | 海南卫康制药(潜山)有限公司 | Metronidazole composition freeze-dried tablet and preparation method thereof |
| CN106137988A (en) * | 2016-01-14 | 2016-11-23 | 上海信谊万象药业股份有限公司 | A kind of metronidazole solid preparation and preparation method thereof |
| CN113975232A (en) * | 2021-10-22 | 2022-01-28 | 北京汇诚益健医药科技有限责任公司 | Pharmaceutical composition of metronidazole benzoate |
-
2006
- 2006-03-28 CN CN 200610066058 patent/CN1817346A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102349894A (en) * | 2011-08-18 | 2012-02-15 | 海南良方医药有限公司 | Benzoylmetronidazole composition and preparation method thereof |
| CN102349894B (en) * | 2011-08-18 | 2013-03-13 | 海南良方医药有限公司 | Benzoylmetronidazole composition and preparation method thereof |
| CN104586749A (en) * | 2014-12-25 | 2015-05-06 | 海南卫康制药(潜山)有限公司 | Metronidazole composition freeze-dried tablet and preparation method thereof |
| CN106137988A (en) * | 2016-01-14 | 2016-11-23 | 上海信谊万象药业股份有限公司 | A kind of metronidazole solid preparation and preparation method thereof |
| CN113975232A (en) * | 2021-10-22 | 2022-01-28 | 北京汇诚益健医药科技有限责任公司 | Pharmaceutical composition of metronidazole benzoate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1038474C (en) | Stable extended release oral composition | |
| CN1131027C (en) | Controlled release formulation for poorly soluble basic drugs | |
| CN101019876B (en) | Compound roxithromycin dispersing tablet | |
| CN1817346A (en) | Benzoyl metronidazole dispersion tablets and preparation thereof | |
| CN101053562A (en) | Otilonium bromide capsule | |
| CN101053565A (en) | Vaginal tablets containing coltrimazole | |
| CN1903183A (en) | Dispersion tablets of telbivudine and its prepn. method | |
| CN1943586A (en) | Oral disintegrating tablet using roxithromycin and ambroxol hydrochloride as active component and its preparing method and use | |
| CN1973838A (en) | Secnidazole tablet and its prepn process | |
| CN1203856C (en) | Dispersion tablet of vasilowy hydrochlaride and its prepn. method | |
| CN113384547A (en) | Omeprazole hydrotalcite composite sheet and preparation process thereof | |
| CN1302764C (en) | Vaginal gel tablets | |
| CN103054820A (en) | Dronedarone hydrochloride pharmaceutical composition and preparation method thereof | |
| CN1287797C (en) | Gancilorvir dispersable tablet and its preparation | |
| CN1304002C (en) | Vaginal effervescence tablet of secnidazole and its preparation | |
| CN1546046A (en) | Adefovir dipivoxil dispersing tablet and its preparation | |
| CN1546029A (en) | Gatifloxacin dispersible tablet and its preparation process | |
| CN1742741A (en) | Medicinal composition containing amino glucose and calcium agent and vitamin D and use thereof | |
| CN1843505A (en) | Compound Doxycycline lysozyme enteral capsule | |
| CN1557319A (en) | Rosuvastatin dispersion tablet and its preparation method | |
| CN1823808A (en) | Clindamycin palmitate hydrochloride dispersion tablet and its preparation method | |
| CN1857296A (en) | Medicine composition with roxithromycin and ambroxol hydrochloride as active components and its preparing method and use | |
| CN1191830C (en) | Orally disintegrating Nifedipine prepn and its recipe | |
| CN1557330A (en) | Sustained release medication of clindamycinum | |
| CN1946379A (en) | Prolonged-release compositions comprising torasemide and a matrix-forming polymer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |